Tucatinib was first approved by the FDA for the treatment of patients with HER2-positive advanced unresectable or metastatic breast cancer in combination with trastuzumab and capecitabine on April 17, 2020.
Kristin Barber, APRN, AOCNP, FNP-BC
Advertisement
Articles by Kristin Barber, APRN, AOCNP, FNP-BC
Adding the immunotherapy to chemotherapy in the frontline setting may improve overall survival for patients with advanced biliary tract cancer.
Advertisement
Latest Updated Articles
Durvalumab Outcomes Could Change Treatment Approaches in CholangiocarcinomaPublished: April 22nd 2022 | Updated:
Oncology Drug Crash Course: Tucatinib and Trastuzumab for HER2+ CRCPublished: June 30th 2023 | Updated:
Advertisement
Advertisement
